secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K/A
Filed at:   2022-12-16T23:59:59+00:00
Accession:  0001493152-22-035788
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa reports Q3 2022 net loss of $3.7M, R&D spend up 473% YoY
----------------------------------------------------------------

- Net loss of $3.693M for Q3 2022 vs $1.879M in Q3 2021; nine-month loss $9.445M.
- R&D expenses surged to $2.334M in Q3 2022 from $0.407M, driven by $1.928M in IC100 drug manufacturing.
- Cash used in operations improved to $1.078M for nine months 2022 from $4.460M in 2021.
- Financing provided $1.353M via preferred stock private placement; no revenue disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315222035788/0001493152-22-035788-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315222035788/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-035788

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer